Lataa...
Pasireotide and Octreotide Stimulate Distinct Patterns of sst(2A) Somatostatin Receptor Phosphorylation
Pasireotide (SOM230) is currently under clinical evaluation as a successor compound to octreotide for the treatment of acromegaly, Cushing’s disease, and carcinoid tumors. Whereas octreotide acts primarily via the sst(2A) somatostatin receptor, pasireotide was designed to exhibit octreotide-like sst...
Tallennettuna:
| Julkaisussa: | Mol Endocrinol |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Endocrine Society
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5428126/ https://ncbi.nlm.nih.gov/pubmed/20051480 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/me.2009-0315 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|